240 related articles for article (PubMed ID: 28765120)
1. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Hennequart M; Pilotte L; Cane S; Hoffmann D; Stroobant V; Plaen E; Van den Eynde BJ
Cancer Immunol Res; 2017 Aug; 5(8):695-709. PubMed ID: 28765120
[TBL] [Abstract][Full Text] [Related]
2. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
[TBL] [Abstract][Full Text] [Related]
3. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer.
Cesario A; Rocca B; Rutella S
Curr Med Chem; 2011; 18(15):2263-71. PubMed ID: 21517752
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.
Iachininoto MG; Nuzzolo ER; Bonanno G; Mariotti A; Procoli A; Locatelli F; De Cristofaro R; Rutella S
Molecules; 2013 Aug; 18(9):10132-45. PubMed ID: 23973990
[TBL] [Abstract][Full Text] [Related]
5. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Göbel C; Breitenbuecher F; Kalkavan H; Hähnel PS; Kasper S; Hoffarth S; Merches K; Schild H; Lang KS; Schuler M
Cell Death Dis; 2014 Dec; 5(12):e1568. PubMed ID: 25501829
[TBL] [Abstract][Full Text] [Related]
6. miR-448 targets IDO1 and regulates CD8
Lou Q; Liu R; Yang X; Li W; Huang L; Wei L; Tan H; Xiang N; Chan K; Chen J; Liu H
J Immunother Cancer; 2019 Aug; 7(1):210. PubMed ID: 31391111
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
Ma WJ; Wang X; Yan WT; Zhou ZG; Pan ZZ; Chen G; Zhang RX
World J Gastroenterol; 2018 May; 24(20):2181-2190. PubMed ID: 29853736
[TBL] [Abstract][Full Text] [Related]
8. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
9. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
10. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
12. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.
Théate I; van Baren N; Pilotte L; Moulin P; Larrieu P; Renauld JC; Hervé C; Gutierrez-Roelens I; Marbaix E; Sempoux C; Van den Eynde BJ
Cancer Immunol Res; 2015 Feb; 3(2):161-72. PubMed ID: 25271151
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
Zhai L; Ladomersky E; Lauing KL; Wu M; Genet M; Gritsina G; Győrffy B; Brastianos PK; Binder DC; Sosman JA; Giles FJ; James CD; Horbinski C; Stupp R; Wainwright DA
Clin Cancer Res; 2017 Nov; 23(21):6650-6660. PubMed ID: 28751450
[No Abstract] [Full Text] [Related]
14. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
[TBL] [Abstract][Full Text] [Related]
15. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
16. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Levina V; Su Y; Gorelik E
Clin Dev Immunol; 2012; 2012():173029. PubMed ID: 22654951
[TBL] [Abstract][Full Text] [Related]
17. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
[TBL] [Abstract][Full Text] [Related]
18. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
19. Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
Hamm CA; Pry K; Lu J; Bacus S
Exp Mol Pathol; 2019 Aug; 109():1-15. PubMed ID: 30953647
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]